These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 32226429)

  • 21. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
    Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
    Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The identification of effective tumor-suppressing neoantigens using a tumor-reactive TIL TCR-pMHC ternary complex.
    Kim SH; Lee BR; Kim SM; Kim S; Kim MS; Kim J; Lee I; Kim HS; Nam GH; Kim IS; Song K; Choi Y; Lee DS; Park WY
    Exp Mol Med; 2024 Jun; 56(6):1461-1471. PubMed ID: 38866910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.
    Toor JS; Rao AA; McShan AC; Yarmarkovich M; Nerli S; Yamaguchi K; Madejska AA; Nguyen S; Tripathi S; Maris JM; Salama SR; Haussler D; Sgourakis NG
    Front Immunol; 2018; 9():99. PubMed ID: 29441070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
    Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrated functional genomics approach for the design of patient-individual antitumor vaccines.
    Weinschenk T; Gouttefangeas C; Schirle M; Obermayr F; Walter S; Schoor O; Kurek R; Loeser W; Bichler KH; Wernet D; Stevanović S; Rammensee HG
    Cancer Res; 2002 Oct; 62(20):5818-27. PubMed ID: 12384544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma.
    Gaudin C; Kremer F; Angevin E; Scott V; Triebel F
    J Immunol; 1999 Feb; 162(3):1730-8. PubMed ID: 9973436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma.
    Matsushita H; Sato Y; Karasaki T; Nakagawa T; Kume H; Ogawa S; Homma Y; Kakimi K
    Cancer Immunol Res; 2016 May; 4(5):463-71. PubMed ID: 26980598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo.
    Jantzer P; Schendel DJ
    Cancer Res; 1998 Jul; 58(14):3078-86. PubMed ID: 9679974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ProTECT-Prediction of T-Cell Epitopes for Cancer Therapy.
    Rao AA; Madejska AA; Pfeil J; Paten B; Salama SR; Haussler D
    Front Immunol; 2020; 11():483296. PubMed ID: 33244314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes.
    Bjerregaard AM; Nielsen M; Jurtz V; Barra CM; Hadrup SR; Szallasi Z; Eklund AC
    Front Immunol; 2017; 8():1566. PubMed ID: 29187854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
    Bernhard H; Jäger E; Maeurer MJ; Meyer zum Büschenfelde KH; Knuth A
    Tissue Antigens; 1996 Jul; 48(1):22-31. PubMed ID: 8864171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.
    Strønen E; Toebes M; Kelderman S; van Buuren MM; Yang W; van Rooij N; Donia M; Böschen ML; Lund-Johansen F; Olweus J; Schumacher TN
    Science; 2016 Jun; 352(6291):1337-41. PubMed ID: 27198675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutated cytochrome b as a determinant of a new monoclonal antibody (H8.98) on renal carcinoma cell lines recognized by a Vgamma3Vdelta1(+) T-cell clone.
    Choudhary A; Kurt RA; Goret F; Moreau A; Diéz E; Urba WJ; Jotereau F; Pourcel C
    Int J Cancer; 1999 Aug; 82(4):562-8. PubMed ID: 10404071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.
    Lu YC; Yao X; Crystal JS; Li YF; El-Gamil M; Gross C; Davis L; Dudley ME; Yang JC; Samuels Y; Rosenberg SA; Robbins PF
    Clin Cancer Res; 2014 Jul; 20(13):3401-10. PubMed ID: 24987109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
    Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
    Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma.
    Kristensen NP; Heeke C; Tvingsholm SA; Borch A; Draghi A; Crowther MD; Carri I; Munk KK; Holm JS; Bjerregaard AM; Bentzen AK; Marquard AM; Szallasi Z; McGranahan N; Andersen R; Nielsen M; Jönsson GB; Donia M; Svane IM; Hadrup SR
    J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 34813506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.
    Mulders P; Tso CL; Pang S; Kaboo R; McBride WH; Hinkel A; Gitlitz B; Dannull J; Figlin R; Belldegrun A
    J Immunother; 1998 May; 21(3):170-80. PubMed ID: 9610908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
    Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
    Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
    [No Abstract]   [Full Text] [Related]  

  • 40. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
    Roerden M; Nelde A; Walz JS
    Front Immunol; 2019; 10():3004. PubMed ID: 31921218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.